You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart

Article: The flexible tail of the hemostatic enzyme adamts13 is able to shield the active site

€3.03

SKU: product-article-19769 Category: General

Description
Reviews (0)

Description

The flexible tail of the hemostatic enzyme adamts13 is able to shield the active site

Reviews

There are no reviews yet.

Be the first to review “Article: The flexible tail of the hemostatic enzyme adamts13 is able to shield the active site”

You must be logged in to post a review.

Top

Article: The flexible tail of the hemostatic enzyme adamts13 is able to shield the active site

Description

Reviews

Related products

Article: Highlights in digestive oncology

Article: Highlights in breast cancer

Article: INTRODUCTION

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer